Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 2
1998 3
1999 1
2000 4
2002 4
2003 2
2004 2
2005 2
2006 1
2007 1
2010 1
2011 2
2012 1
2013 2
2017 1
2018 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma.
Leaf RK, Stroopinsky D, Pyzer AR, Kruisbeek AM, van Wetering S, Washington A, Ephraim A, Cole L, Morin A, Jain S, Nahas MR, Apel A, Arnason J, Hamdan A, Rosenblatt J, Avigan D. Leaf RK, et al. Among authors: van wetering s. J Immunother. 2017 Nov/Dec;40(9):315-322. doi: 10.1097/CJI.0000000000000185. J Immunother. 2017. PMID: 28961609
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.
van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD. van de Loosdrecht AA, et al. Among authors: van wetering s. Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23. Cancer Immunol Immunother. 2018. PMID: 30039426 Free PMC article. Clinical Trial.
Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy.
van den Ancker W, Wijnands PG, Ruben JM, Westers TM, Punt B, Bachas C, Ravenshorst N, van Wetering S, Kruisbeek AM, Bontkes HJ, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD. van den Ancker W, et al. Among authors: van wetering s. Immunotherapy. 2013 Nov;5(11):1183-90. doi: 10.2217/imt.13.125. Immunotherapy. 2013. PMID: 24188673 Clinical Trial.
Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage.
Castellano G, Melchiorre R, Loverre A, Ditonno P, Montinaro V, Rossini M, Divella C, Battaglia M, Lucarelli G, Annunziata G, Palazzo S, Selvaggi FP, Staffieri F, Crovace A, Daha MR, Mannesse M, van Wetering S, Paolo Schena F, Grandaliano G. Castellano G, et al. Among authors: van wetering s. Am J Pathol. 2010 Apr;176(4):1648-59. doi: 10.2353/ajpath.2010.090276. Epub 2010 Feb 11. Am J Pathol. 2010. PMID: 20150432 Free PMC article.
Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy.
van de Ven R, Reurs AW, Wijnands PGJTB, van Wetering S, Kruisbeek AM, Hooijberg E, Scheffer GL, Scheper RJ, de Gruijl TD. van de Ven R, et al. Among authors: van wetering s. Cancer Immunol Immunother. 2012 Feb;61(2):181-191. doi: 10.1007/s00262-011-1039-x. Epub 2011 Aug 27. Cancer Immunol Immunother. 2012. PMID: 21874304
27 results